Objective:To design and optimize a novel medical detection device of prevention and control for nosocomial infection based on quality function deployment(QFD),so as to enhance the safety and prevention efficiency of medical test.Methods:The design requirements of the device of prevention and control for nosocomial infection were systematically analyzed through QFD method.The requirements of users were integrated and converted into special technical characteristics.And then,the novel medical detection device of prevention and control for nosocomial infection based on QFD was designed.Laboratory testing,simulated clinical testing,and a small-scale clinical trial involved 50 patients from Union Hospital,Tongji Medical College,Huazhong University of Science and Technology were adopted to assess the convenience of operation,and reliability and safety of the results of this device in clinical work.Results:A closed detection device that integrated processing sample,reaction detection and pathogen inactivation was designed,which could reduce operational risks and improve detection efficiency.The sensitivity and specificity of the detection of this device were respectively 97.5%and 95.2%in test of laboratory,and error of repeatability was less than±1.5%.The test time of that was shortened from 30 min of test by conventional equipment to 21 min.The accuracy rate of that in testing 50 patients of clinical trial was 96.8%,and average testing time of each case was 3.5 minutes.Conclusion:The novel medical detection device of prevention and control for nosocomial infection that is designed and optimized by QFD method can effectively enhance the safety and efficiency of medical test,and reduce biosafety risks during operations process.It can provide important theoretical support for the design of medical test device in prevention and control for nosocomial infection.

Objective:To design and optimize a novel medical detection device of prevention and control for nosocomial infection based on quality function deployment(QFD),so as to enhance the safety and prevention efficiency of medical test.Methods:The design requirements of the device of prevention and control for nosocomial infection were systematically analyzed through QFD method.The requirements of users were integrated and converted into special technical characteristics.And then,the novel medical detection device of prevention and control for nosocomial infection based on QFD was designed.Laboratory testing,simulated clinical testing,and a small-scale clinical trial involved 50 patients from Union Hospital,Tongji Medical College,Huazhong University of Science and Technology were adopted to assess the convenience of operation,and reliability and safety of the results of this device in clinical work.Results:A closed detection device that integrated processing sample,reaction detection and pathogen inactivation was designed,which could reduce operational risks and improve detection efficiency.The sensitivity and specificity of the detection of this device were respectively 97.5%and 95.2%in test of laboratory,and error of repeatability was less than±1.5%.The test time of that was shortened from 30 min of test by conventional equipment to 21 min.The accuracy rate of that in testing 50 patients of clinical trial was 96.8%,and average testing time of each case was 3.5 minutes.Conclusion:The novel medical detection device of prevention and control for nosocomial infection that is designed and optimized by QFD method can effectively enhance the safety and efficiency of medical test,and reduce biosafety risks during operations process.It can provide important theoretical support for the design of medical test device in prevention and control for nosocomial infection.

Objective:To perform a statistical analysis of the ABO blood group distribution of COVID-19 convalescents, and further analyze the ABO blood group distribution in COVID-19 convalescents with different plasma antibody titer against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Methods:Convalescent plasma was collected from 150 patients aged 18-60 years old who had recovered from COVID-19. Convalescent plasma was collected 14 days later after patients discharged from hospital, and another 180 normal people in Wuhan city were served as healthy control group. Then we analyzed the relationship between age, gender and the ABO blood group distribution. We also tried to clarify the relationship between plasma antibody liter against SARS-CoV-2 and the ABO blood group distribution.Results:Compared with the healthy control group, the proportion of blood group B in COVID-19 convalescents was higher (36% vs 25.0%, χ 2=4.714, P<0.05). The ABO blood group distribution did not differ from male and female COVID-19 convalescents, while age affected the ABO blood group distribution of COVID-19 convalescents. Among the age group under 40 years old, the proportion of blood group B in COVID-19 convalescents was higher than that in the healthy control group (38.5% vs 25.0%, χ 2=5.264, P<0.05). The antibody titer against SARS-CoV-2 in 5.3% of the convalescent plasma was under 1:80. In the high antibody liter against SARS-CoV-2 group, the proportion of blood group B in COVID-19 convalescents was higher than that in the healthy control group (35.2% vs 25.0%, χ 2=3.979, P<0.05). Conclusions:COVID-19 convalescents with blood group B and age group under 40 years old have a higher proportions than that in the normal people. Part of the convalescents with lowantibody liter against SARS-CoV-2 didn’t meet the conditions for plasma donation. Convalescents with blood group B may be more suitable as plasma donators for the therapy of COVID-19.